LCLiting Chen

Liting Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liting Chen has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Jianfeng Zhou

    Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    8 shared publications
  • Yicheng Zhang

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    8 shared publications
  • Chunrui Li

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan

    7 shared publications
  • Di Wang

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China

    7 shared publications
  • Jin Jin

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    7 shared publications
  • Yi Xiao

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    7 shared publications

Latest Publications

  • Open Access

    Light sheet microscopy imaging dataset of CAR-T-cell-mediated cytotoxicity

    by Jie Wang, Jin Jin, Yuekun Fang, Liting Chen, Peng Fei

    Research on CAR-T cell states is crucial for understanding the mechanisms of immunotherapy. Previous studies in live cells have been primarily limited by phototoxicity, resolution, and throughput, making it difficult to conduct further research and observations on cell states. To enable more detailed studies of cell states, we developed a microscopy imaging system with subcellular resolution, low phototoxicity, high imaging throughput, and automated data reconstruction. Using this system, we have generated and shared over 400 image sets that capture the cytotoxic effects of CAR-T cells on tumor cells. The data provide an isotropic spatial resolution of 320 nm, a temporal resolution of up to 2.5 seconds per volume, and long-term observations spanning up to 5 hours. This study reports an imaging system that fills an essential gap in the field, offers valuable insights into the cytotoxic processes of CAR-T cells, and significantly advances research in this area.


  • Open Access

    Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review

    by Qiyang Han, Xiaoying Zhang, Liting Chen, Yicheng Zhang

    Despite the success of vaccination and small-molecule antivirals in significantly reducing mortality from acute viral infections, chronic viral infections


  • Open Access

    Case of Myelodysplastic Syndrome 15 Years After Kidney Transplantation Under Long‐Term Immunosuppression

    by Shuai Su, Sijia Yan, Liting Chen, Yi Xiao

    In solid organ transplant recipients receiving long‐term immunosuppression, persistent or progressive pancytopenia is often initially attributed to infections or drug toxicity, thereby potentially delaying the recognition of clonal myeloid disorders and germline predispositions. We report the case of a kidney transplant recipient who had predominantly maintained tacrolimus‐based immunosuppression and presented with progressive pancytopenia and marked reticulocytopenia. Bone marrow evaluation revealed severe hypocellularity with suppression of granulopoiesis and erythropoiesis, as well as prominent dysmegakaryopoiesis. Flow cytometry showed a small population of immunophenotypically aberrant myeloid blasts, supporting a diagnosis of hypocellular myelodysplastic syndrome. Myeloid gene next‐generation sequencing detected a FANCA missense variant (c.3630C > A; p.F1210L; variant allele frequency 47.2%), prompting consideration of germline‐associated marrow failure or genetic susceptibility and the need for confirmatory testing in nonhematopoietic tissues. During hospitalization, the patient developed severe opportunistic infections that rapidly progressed to respiratory failure and hemodynamic instability. This case highlights the need for early marrow evaluation and genetic risk stratification in transplant recipients with unexplained cytopenia and for the dynamic balancing of hematopoietic rescue against preservation of allograft function to reduce diagnostic delays and subsequent complications.


  • Open Access

    Clinical applications of artificial intelligence in the histopathology of lymphoma: diagnosis, treatment and prognosis

    by Mengyao Kang, Zibo Yang, Tian Yu, Dongyu Li, Zhiqiong Wang, Liting Chen

    Artificial intelligence (AI) is an important branch of computer science. With the rapid development of AI, the application in oncology has become increasingly widespread. As a hematologic malignancy characterized by remarkable heterogeneity, lymphoma has long posed significant challenges in both diagnosis and treatment, particularly with regard to its complex classification and difficulties in prognostic evaluation. Breakthroughs in AI technology have provided a new paradigm for precision treatment of tumors. AI can integrate and analyze HE pathology slides and PET/CT images to enhance diagnostic efficiency; meanwhile, in terms of treatment prognosis, AI can identify biomarkers to accurately classify lymphoma subtypes for therapeutic guidance, simultaneously quantify biomarkers to minimize the influence of subjective variability, and predict the patients’ prognosis based on the extracted features to assist in the precise treatment of lymphoma. This review aims to provide an overview of AI related to various fields of lymphoma, introducing the core technologies and principles of AI, including deep learning, decision trees, regression models, and so on. We also discuss the clinical applications of AI in lymphoma pathology slides and PET/CT images, systematically analyze the clinical applications of AI in diagnosis, treatment, and prognosis, as well as innovatively summarize the cutting-edge applications of AI in 3D pathology of lymphomas, and finally, we emphasize the development potentials and current challenges of AI in the field of lymphomas to promote precision lymphoma diagnosis and treatment by providing a theoretical foundation.


  • Open Access

    Spatio-temporal kinetics of patients’ CAR-T cells in blood and serous cavity effusion: real-world clinical insights

    by Man Zhang, Caixia Chen, Yuekun Fang, Wanying Liu, Xiaoying Zhang, Liting Chen, Yi Xiao

    Background Chimeric antigen receptor (CAR) T cells have long been regarded as living drugs, those activation, diffusion, and expansion influence the clinical efficacy. Dynamic monitoring of CAR-T cells in vivo is crucial for understanding their biodistribution and optimizing therapeutic outcomes. However, due to the challenges in sampling tissue-resident CAR-T cells from patients, limited data have been reported on their spatial and temporal distribution. Methods This study enrolled 43 patients with haematological malignancies receiving CAR-T cell therapy. CAR copy numbers in the peripheral blood (PB) and serous cavity effusion (SCE) were sequentially quantified and analysed. Results High expansion of CAR-T cells in PB was associated with subsequent expansion in SCE. The median Tmax in SCE occurred later than in PB. Patients with immune effector cell-associated neurotoxicity syndrome (ICANS) exhibited higher CAR copy numbers in cerebrospinal fluid (CSF) compared to those without ICANS. Peripheral infection was associated with increased CAR copy numbers in CSF, which may be caused by cell diffusion or/and expansion. Tumour invasion favored local accumulation and expansion of CAR-T cells in pleural effusion or ascites (PE/A), and patients with tumour invasion had a higher incidence of local cytokine release syndrome (L-CRS). Conclusion We characterized the spatial and temporal distribution of CAR-T cells and identified associations between CAR copy numbers and local inflammation, tumour invasion, and adverse events. These findings enhance our understanding of CAR-T cells diffusion, trafficking, and expansion, providing novel insights for clinical management and therapeutic optimization.


  • Open Access

    Adaptive-learning physics-assisted light-field microscopy enables day-long and millisecond-scale super-resolution imaging of 3D subcellular dynamics

    by Lanxin Zhu, Jiahao Sun, Chengqiang Yi, Meng Zhang, Yihang Huang, Sicen Wu, Mian He, Liting Chen, Yicheng Zhang, Chunhong Zheng, et al.

    Long-term and high-spatiotemporal-resolution 3D imaging of living cells remains an unmet challenge for super-resolution microscopy, owing to the noticeable phototoxicity and limited scanning speed. While emerging light-field microscopy can mitigate this issue through three-dimensionally capturing biological dynamics with merely single snapshot, it suffers from suboptimal resolution insufficient for resolving subcellular structures. Here we propose an Adaptive Learning PHysics-Assisted Light-Field Microscopy (Alpha-LFM) with a physics-assisted deep learning framework and adaptive-tuning strategies capable of light-field reconstruction of diverse subcellular dynamics. Alpha-LFM delivers sub-diffraction-limit spatial resolution (up to ~120 nm) while maintaining high temporal resolution and low phototoxicity. It enables rapid and mild 3D super-resolution imaging of diverse intracellular dynamics at hundreds of volumes per second with exceptional details. Using Alpha-LFM approach, we finely resolve the lysosome-mitochondrial interactions, capture rapid motion of peroxisome and the endoplasmic reticulum at 100 volumes per second, and reveal the variations in mitochondrial fission activity throughout two complete cell cycles of 60 h.


  • Open Access

    3D live imaging and phenotyping of CAR-T cell mediated-cytotoxicity using high-throughput Bessel oblique plane microscopy

    by Zhaofei Wang, Jie Wang, Yuxuan Zhao, Jin Jin, Wentian Si, Longbiao Chen, Man Zhang, Yao Zhou, Shiqi Mao, Chunhong Zheng, et al.

    Clarification of the cytotoxic function of T cells is crucial for understanding human immune responses and immunotherapy procedures. Here, we report a high-throughput Bessel oblique plane microscopy (HBOPM) platform capable of 3D live imaging and phenotyping of chimeric antigen receptor (CAR)-modified T-cell cytotoxicity against cancer cells. The HBOPM platform has the following characteristics: an isotropic subcellular resolution of 320 nm, large-scale scouting over 400 interacting cell pairs, long-term observation across 5 hours, and quantitative analysis of the Terabyte-scale 3D, multichannel, time-lapse image datasets. Using this advanced microscopy platform, several key subcellular events in CAR-T cells are captured and comprehensively analyzed; these events include the instantaneous formation of immune synapses and the sustained changes in the microtubing morphology. Furthermore, we identify the actin retrograde flow speed, the actin depletion coefficient, the microtubule polarization and the contact area of the CAR-T/target cell conjugates as essential parameters strongly correlated with CAR-T-cell cytotoxic function. Our approach will be useful for establishing criteria for quantifying T-cell function in individual patients for all T-cell-based immunotherapies.


  • Open Access

    3D live imaging and phenotyping of the subcellular cytotoxicity in cancer immunotherapy using event-triggered Bessel oblique plane microscopy

    by Zhaofei Wang, Jie Wang, Yuxuan Zhao, Jin Jin, Wentian Si, Longbiao Chen, Man Zhang, Yao Zhou, Shiqi Mao, Yicheng Zhang, et al.

    Clarification of the cytotoxic function of T cells is crucial for understanding human immune responses and immunotherapy procedures. Here, we report an event-triggered Bessel oblique plane microscopy (EBOPM) platform capable of smart 3D live imaging and phenotyping of chimeric antigen receptor (CAR)-modified T-cell cytotoxicity in cancer immunotherapy; the EBOPM platform has the following characteristics: an isotropic subcellular resolution of 320 nm, large-scale scouting over 400 interacting cell pairs, long-term observation across 5 hours, and quantitative analysis of the Terabyte-scale 3D, multichannel, time-lapse image datasets. Using this advanced microscopy platform, several key subcellular events in CAR-T cells were captured and comprehensively analyzed; these events included the instantaneous formation of immune synapses and the sustained changes in the microtubing morphology. Furthermore, we identified the actin retrograde flow speed, the actin depletion coefficient, the microtubule polarization and the contact area of the CAR-T/target cell conjugates as essential parameters strongly correlated with CAR-T-cell cytotoxic function. Our approach will be useful for establishing criteria for quantifying T-cell function in individual patients for all T-cell-based immunotherapies.

  • Open Access

    High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy

    by Jin Jin, Li Lin, Jiao Meng, Lijun Jiang, Man Zhang, Yuekun Fang, Wanying Liu, Xiangke Xin, Xiaolu Long, Dong Kuang, et al.


  • Open Access

    Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL

    by Wanying Liu, Jiaying Wu, Xi Ming, Qi Zhang, Delian Zhou, Rubing Zheng, Mi Zhou, Zhen Shang, Liting Chen, Xiaojian Zhu, et al.

    Background: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r/r ALCL, however, this is not an effective treatment for all ALK+ALCL.Case report: Herein, we report a patient with relapsed/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy.Conclusion: The patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness.